Intranasal bremelanotide significantly improved subjective sexual arousal and desire in premenopausal women with sexual arousal disorder in a placebo-controlled RCT — landmark evidence for melanocortin-based female sexual dysfunction treatment.
Key findingIntranasal bremelanotide (PT-141) significantly increased subjective sexual arousal, desire, and genital sensation in premenopausal women with sexual
What the researchers found
Intranasal bremelanotide (PT-141) significantly increased subjective sexual arousal, desire, and genital sensation in premenopausal women with sexual arousal disorder in a double-blind, placebo-controlled RCT — landmark evidence leading toward FDA approval for female sexual dysfunction.
Why it matters
Relevant for pt-141, sexual-health.
How the study worked
RCT study on pt-141, sexual-health.
What this study cannot tell us
See abstract.
How to read the evidence
strong evidence.
When this study was published
Published in 2006.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
The journal of sexual medicine, 3(4), 628-638
Citation
Diamond, Lisa E; Earle, Dennis C; Heiman, Julia R; Rosen, Raymond C; Perelman, Michael A; Harning, Ronald. (2006). An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.. The journal of sexual medicine, 3(4), 628-638. https://doi.org/10.1111/j.1743-6109.2006.00268.x